ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO960

The Neuropeptide SP/NK-1R Axis Promotes Renal Interstitial Fibrosis via MAPK Pathway in Unilateral Ureteral Obstruction Mice

Session Information

  • CKD: Pathobiology - I
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2203 CKD (Non-Dialysis): Mechanisms

Authors

  • Zhu, Enyi, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
  • Zhong, Ming, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
  • Liu, Yang, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
  • Liu, Yu, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
  • Li, Jinhong, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
  • Zheng, Zhihua, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, China
Background

Renal interstitial fibrosis is considered to be the major contributor to chronic progressive kidney function loss, and suggested as a significant predictor of renal survival in chronic kidney disease. The potential mechanism which initiates the profibrogenic process during kidney injury is not completely understood. Substance P (SP) is a proinflammatory neuropeptide that binds to its high-affinity receptor neurokinin1-receptor (NK-1R) and it has been involved in multiple fibrotic diseases. However, the role of SP/NK-1R axis in renal interstitial fibrosis is largely undefined.

Methods

To investigate the role of SP/NK-1R in renal interstitial fibrosis, mice were administrated with NK-1R pharmacological inhibitor or SP during unilateral ureteral obstruction (UUO) and NK-1R−/− mice were subjected to UUO. Cell counting, colony formation, apoptosis, cell cycle and RNA-seq analysis were performed in tubular epithelium cells to explore the mechanism of SP/NK-1R.

Results

SP and NK-1R were overexpressed in renal tubular epithelial cells of mice after UUO. In addition, pharmacological and genetic inhibition of NK-1R resulted in reduction of interstitial inflammation, fibrosis and renal cell apoptosis, whereas SP treatment aggravated UUO-induced progressive damage. In vitro, SP administration suppressed growth of NK-1R-overexpressed HK-2 cells, and promoted apoptosis, G2/M arrest and expression of profibrogenic genes, which could be dramatically rescued by NK-1R inhibitor. Mechanistically, RNA-seq analysis revealed that differential expressed genes between NK-1R-ovexpressed HK-2 cells with and without SP treatment were mainly enriched in MAPK signaling. Consistently, phosphorylated p38/JNK levels were increased in SP-treated cells and mice obstructed kidneys. Furthermore, inhibition of NK-1R decreased expression of phosphorylated p38/JNK in SP-treated cells and mice subjected to UUO. In support, the p38 or JNK specific inhibitors partly alleviated SP-mediated effect, and intriguingly, combined use of p38/JNK inhibitors further ameliorated it.

Conclusion

These results demonstrate that neuropeptide SP/NK-1R axis plays an important role in kidney interstitial fibrosis via activating the MAPK pathway of renal tubular epithelial cells, which may be a promising therapeutic target for chronic kidney disease.